ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
63,870.16
1.56%
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs Yen
153.055
0.01%
Brent Oil
82.765
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Soligenix Inc (SNGX)

  7. Soligenix Inc (SNGX) ニュース

SNGX Soligenix Inc

0.418
0.0135 (3.34%)
2024年5月4日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Soligenix Inc SNGX NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
Upgrade Icon
0.0135 3.34% 0.418 08:59:38
始値 安値 高値 終値 前日終値
0.402 0.3958 0.4297 0.4045 0.4045
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/2520:30PRNUSSoligenix Extends Patent Protection for its Filovirus..
2024/4/1821:30PRNUSSoligenix Announces Pricing of $4.75 Million Public Offering
2024/4/1520:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
2024/4/1120:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
2024/4/0320:30PRNUSSoligenix Announces Agreement on the Design of a Second..
2024/3/1520:30PRNUSSoligenix Announces Recent Accomplishments and Year End 2023..
2024/2/0821:30PRNUSSoligenix Announces Formation of Behçet's Disease Medical..
2024/1/2521:30PRNUSSoligenix to Present at The Microcap Conference
2024/1/0821:30PRNUSFDA Grants Soligenix "Fast Track" Designation for Dusquetide..
2024/1/0421:30PRNUSSoligenix Announces Top-line Results of the Phase 2a Study..
2024/1/0221:30PRNUSSoligenix Announces Publication Demonstrating Complete..
2023/12/2306:05EDGAR2Form 8-K - Current report
2023/12/1814:15EDGAR2Form EFFECT - Notice of Effectiveness
2023/12/1606:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1606:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1606:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1606:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1606:03EDGAR2Form 8-K - Current report
2023/12/0907:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0907:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0907:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0907:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0906:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
2023/12/0121:30PRNUS"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma"..
2023/11/3021:30PRNUSSoligenix Receives FDA IND Clearance for Phase 2 Clinical..
2023/11/1806:05EDGAR2Form 8-K - Current report
2023/11/1806:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
2023/11/1406:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/1321:30PRNUSSoligenix Announces Recent Accomplishments And Third Quarter..
2023/10/2105:05EDGAR2Form 8-K - Current report
2023/10/2105:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
2023/10/1802:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/10/1802:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/10/1705:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/10/1620:30PRNUSSoligenix to Present at The ThinkEquity Conference
2023/10/1402:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/9/2520:30PRNUSSoligenix Announces Achievement of Two-Year Stability with..
2023/9/2305:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/9/2305:05EDGAR2Form 8-K - Current report
2023/9/2305:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
2023/9/1605:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/9/1605:05EDGAR2Form 8-K - Current report
2023/8/3105:05EDGAR2Form S-3 - Registration statement under Securities Act of..
2023/8/2206:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/2120:30PRNUSSoligenix Announces Recent Accomplishments And Second..
2023/8/1505:09EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
2023/8/1020:30PRNUSHyBryte™ Expanded Treatment Trial in Cutaneous T-Cell..
2023/8/0805:07EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/8/0805:05EDGAR2Form DEF 14A - Other definitive proxy statements
2023/7/1120:30PRNUSSoligenix Announces Expansion of SGX302 (Synthetic..

最近閲覧した銘柄

NASDAQ
SNGX
Soligenix
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有